Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRVO | CervoMed Inc.

Index- P/E- EPS (ttm)-6.41 Insider Own0.10% Shs Outstand5.70M Perf Week-5.71%
Market Cap24.16M Forward P/E- EPS next Y-5.59 Insider Trans0.00% Shs Float3.30M Perf Month-13.81%
Income-13.10M PEG- EPS next Q- Inst Own9.60% Short Float / Ratio1.00% / 0.61 Perf Quarter-13.24%
Sales1.41M P/S17.16 EPS this Y38.00% Inst Trans-3.65% Short Interest0.03M Perf Half Y-47.26%
Book/sh6.97 P/B0.66 EPS next Y- ROA-63.00% Target Price17.00 Perf Year-45.97%
Cash/sh2.87 P/C1.61 EPS next 5Y- ROE-70.00% 52W Range4.14 - 14.37 Perf YTD-39.10%
Dividend- P/FCF- EPS past 5Y49.10% ROI- 52W High-67.85% Beta1.73
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low11.59% ATR0.69
Employees13 Current Ratio10.70 Sales Q/Q- Oper. Margin- RSI (14)41.35 Volatility13.72% 11.92%
OptionableNo Debt/Eq0.00 EPS Q/Q49.60% Profit Margin- Rel Volume0.69 Prev Close4.90
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume54.55K Price4.62
Recom2.00 SMA20-13.82% SMA50-10.73% SMA200-32.63% Volume37,909 Change-5.71%
Date Action Analyst Rating Change Price Target Change
Nov-17-20Downgrade H.C. Wainwright Buy → Neutral
Mar-21-18Initiated H.C. Wainwright Buy $1.25
Sep-18-23 10:40AM
Sep-05-23 07:00AM
Aug-21-23 08:16AM
Aug-15-23 04:01PM
Mar-30-23 07:00AM
06:30AM Loading…
Dec-16-22 06:30AM
Dec-05-22 06:30AM
Dec-01-22 07:55AM
Nov-17-22 05:20PM
Nov-14-22 04:01PM
Oct-25-22 06:30AM
Aug-17-22 08:52AM
Aug-11-22 06:48PM
Jul-26-22 07:30AM
07:30AM Loading…
Jun-23-22 07:30AM
May-20-22 08:10AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 04:05PM
May-04-22 07:20AM
Apr-18-22 10:42AM
Apr-11-22 07:20AM
Apr-08-22 07:20AM
Apr-06-22 10:15AM
Mar-23-22 10:20AM
Mar-21-22 07:20AM
Mar-09-22 04:56AM
Feb-24-22 07:02AM
07:02AM Loading…
Dec-20-21 07:02AM
Dec-16-21 08:59AM
Dec-01-21 07:02AM
Nov-30-21 11:57AM
Nov-29-21 06:27AM
Nov-22-21 07:02AM
Nov-10-21 07:02AM
Oct-28-21 07:30AM
Sep-10-21 07:02AM
Sep-09-21 07:32AM
Sep-08-21 07:32AM
Aug-30-21 07:32AM
Aug-19-21 06:05AM
Aug-11-21 07:32AM
Aug-06-21 10:20AM
Jul-06-21 06:34AM
Jun-30-21 11:14AM
Jun-28-21 08:35AM
Jun-21-21 08:35AM
Jun-18-21 07:35AM
Jun-13-21 06:13PM
May-14-21 08:21AM
May-10-21 10:23AM
Mar-25-21 11:47AM
Mar-18-21 07:05AM
Mar-17-21 07:05AM
Mar-14-21 04:47AM
Mar-04-21 04:05PM
Feb-18-21 04:05PM
Feb-17-21 04:13PM
Feb-16-21 09:18AM
Feb-11-21 10:02PM
Jan-11-21 07:30AM
Dec-04-20 07:20AM
Nov-29-20 07:29PM
Nov-18-20 11:55AM
Nov-12-20 04:02PM
Oct-19-20 08:00AM
Sep-24-20 08:00AM
Sep-17-20 03:40PM
Sep-15-20 07:12AM
Sep-11-20 08:30AM
Sep-10-20 08:00AM
Sep-08-20 04:02PM
Sep-01-20 04:02PM
Aug-24-20 08:32AM
Aug-10-20 08:00AM
Jul-27-20 08:00AM
Jul-07-20 08:00AM
Jul-06-20 07:47PM
Jun-11-20 08:00AM
Jun-01-20 08:00AM
May-26-20 08:00AM
May-20-20 01:00PM
May-19-20 03:18PM
May-18-20 09:05AM
May-11-20 04:11PM
May-05-20 08:00AM
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.